Effects of genetic variants in SLC22A2 organic cation transporter 2 and SLC47A1 multidrug and toxin extrusion 1 transporter on cisplatin-induced adverse events

Clinical and Experimental Nephrology

Volumn 16, Issue 6, 2012, Pages 843-851

  Iwata, Kazufumi ^a,b   Aizawa, Keiji ^a   Kamitsu, Saori ^a   Jingami, Sachiko ^a   Fukunaga, Eiko ^a   Yoshida, Minoru ^a   Yoshimura, Misato ^b   Hamada, Akinobu ^b,c   Saito, Hideyuki ^b,c  

^a JAPANESE RED CROSS KUMAMOTO HOSPITAL   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

^c KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Cisplatin; Multidrug and toxin extrusion 1; Nephrotoxicity; Organic cation transporter 2; Single nucleotide polymorphism; SLC22A2; SLC47A1

Indexed keywords

CISPLATIN; DOCETAXEL; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; IRINOTECAN; MEMBRANE PROTEIN; MULTIDRUG AND TOXIN EXTRUSION 1 TRANSPORTER; NAVELBINE; ORGANIC CATION TRANSPORTER 2; PEMETREXED; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CARCINOMA; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; DRUG SAFETY; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; POTASSIUM BLOOD LEVEL; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SODIUM BLOOD LEVEL; THROMBOCYTE COUNT; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ANTINEOPLASTIC AGENTS; CARCINOMA; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLOMERULAR FILTRATION RATE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; ORGANIC CATION TRANSPORT PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; RENAL INSUFFICIENCY;

EID: 84876296735     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-012-0638-y     Document Type: Article

References (25)

1. Schrier RW. Cancer therapy and renal injury. J Clin Invest. 2002;110:743-5.
2. Deng J, Kohda Y, Chiao H, Wang Y, Hu X, Hewitt SM, et al. Interleukin-10 inhibits ischemic and cisplatin-induced acute renal injury. Kidney Int. 2001;60:2118-28.
3. Ramesh G, Reeves WB. TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest. 2002;110:835-42.
4. Lieberthal W, Triaca V, Levine J. Mechanisms of death induced by cisplatin in proximal tubular epithelial cells: apoptosis vs. necrosis. Am J Physiol. 1996;270:F700-8.
5. Pritchard JB, Miller DS. Renal secretion of organic anions and cations. Kidney Int. 1996;49:1649-54.
6. Inui K, Masuda S, Saito H. Cellular and molecular aspects of drug transport in the kidney. Kidney Int. 2000;58:944-58.
7. Okuda M, Saito H, Urakami Y, Takano M, Inui K. cDNA cloning and functional expression of a novel rat kidney organic cation transporter, OCT2. Biochem Biophys Res Commun. 1996;224:500-7.
8. + antiporter in the kidney. Drug Metab Dispos. 2006;34:1868-74.
9. +/organic cation antiporter MATE1. Pharm Res. 2006;23:1696-701.
10. Otsuka M, Matsumoto T, Morimoto R, Arioka S, Omote H, Moriyama Y. A human transporter protein that mediates the final excretion step for toxic organic cations. Proc Natl Acad Sci USA. 2005;102:17923-8.
11. Filipski KK, Mathijssen RH, Mikkelsen TS, Schinkel AH, Sparreboom A. Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin Pharmacol Ther. 2009;86:396-402.
12. Filipski KK, Loos WJ, Verweij J, Sparreboom A. Interaction of cisplatin with the human organic cation transporter 2. Clin Cancer Res. 2008;14:3875-80.
13. Ha Choi J, Wah Yee S, Kim MJ, Nguyen L, Ho Lee J, Kang JO, et al. Identification and characterization of novel polymorphisms in the basal promoter of the human transporter, MATE1. Pharmacogenet Genomics. 2009;19:770-80.
14. Chen Y, Teranishi K, Li S, Yee SW, Hesselson S, Stryke D, et al. Genetic variants in multidrug and toxic compound extrusion-1, hMATE1, alter transport function. Pharmacogenomics J. 2009;9:127-36.
15. Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study. Diabetes. 2009;58:745-9.
16. Yokoo K, Murakami R, Matsuzaki T, Yoshitome K, Hamada A, Saito H. Enhanced renal accumulation of cisplatin via renal organic cation transporter deteriorates acute kidney injury in hypomagnesemic rats. Clin Exp Nephrol. 2009;13:578-84.
17. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982-92.
18. Song IS, Shin HJ, Shim EJ, Jung IS, Kim WY, Shon JH, et al. Genetic variants of the organic cation transporter 2 influence the disposition of metformin. Clin Pharmacol Ther. 2008;84:559-62.
19. Wang ZJ, Yin OQ, Tomlinson B, Chow MS. OCT2 polymorphisms and in vivo renal functional consequence: studies with metformin and cimetidine. Pharmacogenet Genomics. 2008;18:637-45.
20. Hutchison FN, Perez EA, Gandara DR, Lawrence HJ, Kaysen GA. Renal salt wasting in patients treated with cisplatin. Ann Intern Med. 1988;108:21-5.
21. Cornelison TL, Reed E. Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol Oncol. 1993;50:147-58.
22. Meyer KB, Madias NE. Cisplatin nephrotoxicity. Miner Electrolyte Metab. 1994;20:201-13.
23. Kim YK, Byun HS, Kim YH, Woo JS, Lee SH. Effect of cisplatin on renal function in rabbits: mechanism of reduced glucose reabsorption. Toxicol Appl Pharmacol. 1995;130:19-26.
24. + transport, and cisplatin-induced apoptosis in renal cells. J Biol Chem. 2002;277:43377-8823.
25. Yonezawa A, Masuda S, Yokoo S, Katsura T, Inui K. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006;319:879-86.